Tarrant Texas Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center

• Category: Corporations - Public - Licenses
• State: Multi-State
• County: Tarrant
• Control #: US-EG-9161
• Format: Word; Rich Text

Description

Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center at Forth Worth dated July 1, 1996. 2 pages The Tarrant Texas Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a legally binding contract that outlines the terms and conditions of a licensing agreement between the two parties. This agreement allows Gentling, Inc. to obtain certain rights to the intellectual property or technology developed by the University of North Texas Health Science Center. Gentling, Inc. is a biotechnology company specializing in genetic analysis and personalized health management, while the University of North Texas Health Science Center is a renowned educational institution that conducts extensive research in the field of healthcare and biotechnology. The Collateral License Agreement grants Gentling, Inc. the exclusive or non-exclusive rights to license and commercialize specific intellectual property developed by the University. This may include patented technologies, research findings, software, or any other innovation related to the agreed-upon field of study. One possible type of Tarrant Texas Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center would be focused on a particular research project or product. In this case, the agreement would outline the specific technology or intellectual property being licensed and the purpose or field of use. Another type of agreement might encompass a broader scope, granting Gentling, Inc. access to multiple technologies or intellectual property developed by the University. This type of agreement could cover various areas of study or research, allowing Gentling, Inc. to explore different avenues of commercialization and product development. The Tarrant Texas Collateral License Agreement is crucial for both parties involved. For Gentling, Inc., it provides a strategic advantage by allowing access to cutting-edge technologies or research findings, enabling them to develop innovative products and services. On the other hand, the University of North Texas Health Science Center benefits from the collaborative efforts with Gentling, Inc., which could result in additional funding, increased exposure, and the potential for their intellectual property to be brought to the market. In summary, the Tarrant Texas Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a significant partnership that fosters collaboration, innovation, and commercialization of intellectual property. It enables Gentling, Inc. to leverage the University's research and technology, fostering advancements in personalized health management and promoting the growth of both entities.

The Tarrant Texas Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a legally binding contract that outlines the terms and conditions of a licensing agreement between the two parties. This agreement allows Gentling, Inc. to obtain certain rights to the intellectual property or technology developed by the University of North Texas Health Science Center. Gentling, Inc. is a biotechnology company specializing in genetic analysis and personalized health management, while the University of North Texas Health Science Center is a renowned educational institution that conducts extensive research in the field of healthcare and biotechnology. The Collateral License Agreement grants Gentling, Inc. the exclusive or non-exclusive rights to license and commercialize specific intellectual property developed by the University. This may include patented technologies, research findings, software, or any other innovation related to the agreed-upon field of study. One possible type of Tarrant Texas Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center would be focused on a particular research project or product. In this case, the agreement would outline the specific technology or intellectual property being licensed and the purpose or field of use. Another type of agreement might encompass a broader scope, granting Gentling, Inc. access to multiple technologies or intellectual property developed by the University. This type of agreement could cover various areas of study or research, allowing Gentling, Inc. to explore different avenues of commercialization and product development. The Tarrant Texas Collateral License Agreement is crucial for both parties involved. For Gentling, Inc., it provides a strategic advantage by allowing access to cutting-edge technologies or research findings, enabling them to develop innovative products and services. On the other hand, the University of North Texas Health Science Center benefits from the collaborative efforts with Gentling, Inc., which could result in additional funding, increased exposure, and the potential for their intellectual property to be brought to the market. In summary, the Tarrant Texas Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a significant partnership that fosters collaboration, innovation, and commercialization of intellectual property. It enables Gentling, Inc. to leverage the University's research and technology, fostering advancements in personalized health management and promoting the growth of both entities.